There is a clinical trial is about to conclude in 2022 (EVEREST).
This study is on 1545 kidney cancer patients who’ve undergone surgery to remove their tumor.
Purpose The goal of the study is to compare how long you live without return of the tumor and how long you live in patients with renal cell cancer randomly (like the flip of a coin) assigned to 54 weeks of everolimus versus 54 weeks of placebo (an inactive drug) after complete or partial removal of your kidney by surgery. The study will also compare the amount and type of side effects between the two study arms.
Dosing: 1 yrs of daily 2.5-10mg Everolimus use. Then follow them for 10 yrs.
It’ll be interesting to see if non-cancer mortality will drop after 1 yr of intense Evorolimus.